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Abstract
Purpose Inhibition of vascular endothelial growth factor
(VEGF) is a promising strategy to treat retinal complications
of diabetes. In contrast to VEGF-A binding ranibizumab,
aflibercept also binds to other members of the VEGF family
including VEGF-B, but potential effects of this factor on per-
meability and angiogenic processes are unclear. Therefore, we
studied how VEGF-B variants as single agents or together
with VEGF-A165 might affect proliferation, migration, or bar-
rier function of retinal endothelial cells (REC). Also investi-
gated was the normalization of REC properties with both
VEGF-inhibitors to explore if additional targeting of VEGF-
B is relevant.
Methods Stimulation of proliferation or migration of immor-
talized bovine REC (iBREC) and disturbance of their barrier
by exposure to VEGF-B variants (as single factors or together
with VEGF-A165) was determined with or without VEGF-
binding proteins being added. Permeability of iBREC was
assessed by measuring their transendothelial resistance
(TER) and expression of the tight junction protein claudin-1.
Results VEGF-B167 and VEGF-B186 enhanced proliferation
of iBREC but these isoforms did not affect cell migration.
Interestingly, ranibizumab completely blocked both migration
and proliferation induced by VEGF-A plus VEGF-B. Both
VEGF-B variants did also not affect barrier function or
claudin-1 expression in a normal or high-glucose
environment. Accordingly, binding VEGF-A was enough to
normalize a reduced TER and reinstate claudin-1 lost during
treatment with this factor in combination with VEGF-B.
Conclusions Important properties and functions of REC seem
not to be affected by any VEGF-B variant and targeting the
key factor VEGF-A is sufficient to normalize growth factor-
disturbed cells of this type.
Keywords Retinal endothelial cells . VEGF-B . Diabetic
retinopathy . VEGF-inhibition
Introduction
Members of the vascular endothelial growth factor (VEGF)
family differently act upon retinal endothelial cells (REC):
splice variants of VEGF-A, (VEGF-A121 and VEGF-A165)
and of placenta growth factor (PlGF-1 and PlGF-2) stimulated
proliferation of primary bovine REC (BREC) and immortal-
ized BREC (iBREC), but only VEGF-A165 stimulated their
migration and elevated their permeability [1–7]. Increased
permeability of iBREC and human REC (HREC) monolayers
induced by long-term exposure to VEGF-A165 correlated with
loss of the tight junction (TJ) protein claudin-1, which became
undetectable in the plasma membrane [3, 5, 8]. VEGF-B, an-
other distinct member of the VEGF family, is expressed in the
two differently spliced and proteolytically processed variants
VEGF-B167 and VEGF-B186 [9–11]. Both variants are
expressed in various normal tissues including ocular structures
with VEGF-B167 typically being the dominant form, whereas
an increased and predominant expression of VEGF-B186 was
measured in malignant tumors [12]. Their 150 C-terminal
amino acids are identical but they have distinct N-terminal
ends resulting in different association with components of
the extracellular matrix which bind VEGF-B167 , but not
VEGF-B186 [10]. Similar to VEGF-A, both VEGF-B variants
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bind to VEGF receptor 1 (VEGFR1) and the non-tyrosine
kinase receptor neuropilin (NRP), but in contrast to VEGF-
A, they are not able additionally to activate VEGFR2 [11, 13].
Concerning the potential physiological functions of VEGF-B,
contradictory results have been reported: there is some evi-
dence that VEGF-B can act as a protective factor ensuring
the survival of vascular endothelial cells and pericytes. For
different cell types and experimental settings, VEGF-B was
found to be either pro-angiogenic or anti-angiogenic [14].
VEGF-B is expressed by cells in the adult murine choroid,
primary BREC, and pericytes [15, 16]. Although lack of
VEGF-B did not affect the development of retinal vasculature
under normal conditions, inhibition of VEGF-B resulted in
decreased laser-induced choroidal neovascularization and
ischemia-caused retinal neovascularization [15, 17]. If
VEGF-B167 can stimulate proliferation or migration of
(retinal) EC was investigated in vitro, but the results were
not coherent [15, 18, 19]. Potential effects of VEGF-B on
vascular permeability are also discussed controversially: over-
expression of VEGF-B186 in the murine choroid resulted in
choroidal neovascularization associated with an increased per-
meability, but similar effects were not observed in the murine
brain [14, 20, 21]. In pursuit to further clarify VEGF-B’s
physiological function it was observed that at least the splice
variant VEGF-B186 is neuroprotective [21].
Pathogenesis and further development of diabetic retinop-
athy (DR) is associated with de-regulated expression of mem-
bers of the VEGF-family: elevated levels of VEGF-A in the
vitreous fluid were observed at all stages of DR, and PlGFwas
found up-regulated after transition to the proliferative form
[22, 23]. Aqueous humor levels of PlGFwere also significant-
ly increased in eyes of patients with proliferative DR and
diabetic macular edema (DME) [24]. VEGF-B was detected
in the vitreous fluids of non-diabetic individuals at very low
concentrations which were only slightly elevated in patients
with DR [25]. Suppression of the detrimental effects of
VEGF-A with the VEGF-binding proteins ranibizumab or
aflibercept is a promising strategy to treat DR or DME which
is likely caused by elevated permeability of REC [26–29]. In
vitro, binding of VEGF-A by ranibizumab was sufficient to
restore or prevent completely the VEGF-A-induced distur-
bance of the iBREC barrier or migration of these cells, even
in the presence of other growth factors when surplus prolifer-
ation was only partly blocked [3, 5–7, 30]. Complete inhibi-
tion of iBREC proliferation stimulated by VEGF-A,
PlGF, or a combination of both was achieved with
aflibercept which can bind VEGF-A, VEGF-B, and
PlGF [31–33]. However, aflibercept and ranibizumab
both efficiently restored a functional iBREC barrier after
extended treatment with complex growth factor mixes
containing VEGF-A and PlGF [7].
To evaluate the potential effects of VEGF-B on important
REC properties and functions, we studied whether presence of
the variants VEGF-B167 or VEGF-B186, as single agents or in
concert with VEGF-A165, affected proliferation or migration
rates. In addition, changes of transendothelial resistance of an
iBRECmonolayer and of the amount or localization of the TJ-
protein claudin-1 as markers for a functional REC barrier were
measured during extended treatment with the above-
mentioned growth factors. In view of a postulated anti-
angiogenic effect of VEGF-B, improvement of the barrier
function by counteracting VEGF-Awas considered a possible
outcome. As a question of potential therapeutic relevance, it
was also investigated if binding VEGF-A with ranibizumab
was sufficient to revert the effects induced by combinations of
VEGF-A and VEGF-B variants or whether aflibercept was
superior due to additional targeting of VEGF-B.
Materials and methods
Reagents, antibodies, and media
Recombinant human growth factors rhVEGF-A165 (SF21-
expressed), rhVEGF-B167 (E. coli-expressed), and recombi-
nant murine rmVEGF-B186 (SF21-expressed) were purchased
from R&D Systems (Wiesbaden, Germany). The F(ab) frag-
ment ranibizumab (10 mg/ml; Lucentis) of a humanized
VEGF-A-binding antibody was a gift from Novartis Pharma
GmbH (Nuremberg, Germany) [30]. The recombinant protein
aflibercept (40 mg/ml; Eylea) consists of the VEGF binding
domain 2 of VEGFR1, the binding domain 3 of VEGFR2, and
an IgG-Fc part and was purchased from Bayer Health Care
(Leverkusen, Germany) [32]. The humanized anti-VEGF-A
antibody bevacizumab (25 mg/ml; Avastin from Roche
Pharma, Grenzach-Wyhlen, Germany) was repackaged at the
pharmacy of the University Hospital Ulm and provided in
syringes which were stored at 4 °C [34]. In the laboratory,
portions of the antibody were stored for less than 4 weeks in
inert plastic vials. The CD20-specific humanized monoclonal
antibody rituximab (10 mg/ml; MabThera) was purchased
from Roche Pharma, and aliquot parts were stored in inert
plastic vials at 4 °C [35]. Rabbit polyclonal antibodies binding
to human claudin-1 (JAY.8) and detection antibodies for fluo-
rescence microscopy (F(ab)2 conjugated with AlexaFluor
594) were from Life Technologies (Karlsruhe, Germany),
and horseradish peroxidase-conjugated detection antibodies
directed against rabbit or mouse IgG from BioRad (Munich,
Germany).
Cultivation of iBREC
Telomerase-immortalized microvascular endothelial cells
from bovine retina (iBREC) were established and character-
ized in our laboratory [2]. The amount of human telomerase
reverse transcriptase measured in iBRECwas similar to that of
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the bovine homologue expressed by shortly cultivated prima-
ry BREC and did not result in significant changes of the phe-
notype: more than 99 % of the iBREC in a typical culture
express von Willebrand factor, vascular endothelial cadherin,
TJ-proteins claudin-1, claudin-3, claudin-5, and ZO-1, as well
as VEGF receptors VEGFR1, VEGFR2, and neuropilin-1
which was confirmed every few weeks during prolonged cul-
tivation. In addition, maintenance of cobblestone morphology
was monitored every other day by microscopy. Although of
bovine origin, iBREC can be stimulated with human growth
factors, and reproducible responses were also considered in-
dicative of a stable and authentic cell system ([2, 3, 5–7];
summarized in supplementary Table 1). iBREC were cultivat-
ed in Endothelial Cell Growth Medium MV (ECGM;
Promocell, Heidelberg, Germany) containing 1 g/l glucose,
0.4 % Endothelial Cell Growth Supplement/H (ECGS/H,
90 μg/ml Heparin), 10 ng/ml epidermal growth factor, 103
nM hydrocortisone, and 5 % fetal calf serum (FCS) on
fibronectin-coated (50 μg/ml; BD Biosciences, Corning,
Amsterdam, the Netherlands) surfaces as previously described
[2, 5]. Cells were used in the experiments at passages 20 to 40
counting from the stage of primary culture, for which stable
expression of relevant proteins and reproducible response to
growth factors had been confirmed. After cultivation for
3 days the confluent iBREC monolayer had formed a tight
barrier indicated by a stable transendothelial resistance of
~50 Ohm × cm2 which is similar to values reported for mono-
layers of primary BREC or HREC [8, 36].
Cell proliferation assay
After cultivation in serum-free medium (SFM; containing
0.4 % ECGS/H, 1 μg/ml fibronectin and 103 nM hydrocorti-
sone) for 24 h, iBRECwere exposed for 48 h to growth factors
VEGF-A165, VEGF-B167, or VEGF-B186 as single agents or in
combination, in the presence or absence of 100 μg/ml
ranibizumab or 250 μg/ml aflibercept in SFM. Enzymatic
conversion of WST-1 (Roche Diagnostics, Mannheim,
Germany), indicative of proliferating cells, was determined
as described [3, 31]. Values were normalized in relation to
those obtained with control cells not treated with effectors.
Results were shown only of experiments in which iBREC
were treated with growth factors for 48 h because different
effects were not observed during shorter or prolonged
exposure.
Cell migration assay
Transmembrane cell migration assays were performed in a
modified Boyden chamber consisting of 12-well cell culture
plates and inserts with a porous membrane (pore size 8.0 μm,
∅1 cm; Falcon, Corning) as previously described [3]. Their
lower compartments were filled with SFM (without ECGS/H,
but containing 5 μg/ml fibronectin) which was supplemented
with VEGF-B167 or VEGF-B186 or these factors in combina-
tion with VEGF-A165 (25 μg/ml final concentration of each)
with or without ranibizumab (6 or 60 μg/ml) or aflibercept (15
or 150 μg/ml). Inserted membranes were initially incubated
for 1 h at 37 °C before 400 μl SFM (without ECGS/H and
fibronectin) and a suspension of 105 iBREC in 100 μl of this
medium were added subsequently to the upper compartment.
After 20 h at 37 °C, migration of cells through the pores of the
membrane was assessed as described [3]. Values were normal-
ized in relation to those obtained with control cells not treated
with effectors.
Treatment of iBREC with growth factors or inhibitors
and subsequent analyses by Western blot
and immunofluorescence staining
Prior to experiments with confluent iBREC, ECGM was re-
placed with serum-reduced medium (SRM, containing 0.4 %
ECGS/H, 0.25 % FCS, 1 μg/ml fibronectin and 103 nM hy-
drocortisone) for 24 h. Cells were incubated for up to 2 days
with single growth factors (10 to 100 ng/ml) or combinations
(each growth factor at 50 ng/ml) before cell extracts were
prepared. To investigate the potential of VEGF-binding pro-
teins in restoring the barrier function of confluent iBREC,
cells in SRMwere pretreated with VEGF-A165 in combination
with VEGF-B167 or VEGF-B186 (each growth factor at
50 ng/ml) for 30 h. Then the medium was changed to SRM
containing the growth factors together with 0.1 to 100 μg/ml
ranibizumab (≈2 to 2,000 nM), 0.25 to 250 μg/ml aflibercept
(≈2 to 2,000 nM), 250 μg/ml bevacizumab, or rituximab
(≈2 μM) before cell extracts were prepared 24 h later [5,
31]. Western blot analyses of whole cell extracts were per-
formed as described [5]. After exposure of confluent mono-
layers of iBREC on fibronectin-coated, two-chamber slides
with effectors, cells were fixed and claudin-1 visualized by
immunofluorescence staining as described [3].
Measurement of transendothelial electrical resistance
To assess parace l lu la r pe rmeab i l i ty of iBREC,
transendothelial electrical resistance (TER) was measured as
described previously with minor modifications using
polyethylenterephthalate membrane inserts (0.3 cm2, pore size
0.4 μm; Costar, Corning) coated overnight with 50 μg/ml
fibronectin at 4 °C [5, 7]. Confluent iBREC monolayers
formed after 3 to 4 days of cultivation were treated as de-
scribed above and TER was measured at different time points
(3, 6, 24, 30, 48, 52, and 72 h) after the addition of effectors.
To avoid temperature-induced changes in TER, plates were
kept on a warm plate at 37 °C during measurements.
Normalized TER values were calculated in relation to the
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TER measured immediately before the medium was replaced
by fresh medium containing the effectors.
General considerations and statistical analyses
In all experiments, control cells were processed identically in
medium only lacking the effector(s) under investigation. All
experiments were repeated several times and in each experi-
ment data were generated frommultiple replicates. TheMann-
Whitney U test was used to compare sets of experimental data
and differences resulting in p-values below 0.05 were consid-
ered significant. Results were presented as conventional box-




proliferation and migration of iBREC
Because an involvement of VEGF-B splice variants in angio-
genesis had been suggested, their effect on iBREC prolifera-
tion was studied: serum-starved cells were exposed to
10 ng/ml VEGF-A165, 1 to 100 ng/ml VEGF-B167 or VEGF-
B186 for 2 days before conversion of WST-1 was determined
as a measure of cell proliferation. Both VEGF-B isoforms
enhanced proliferation of iBREC like VEGF-A165,
confirming their induction of receptor-mediated signal trans-
duction in these cells (Fig. 1a, b). However, when VEGF-A165
was present, they did not in any way modulate its effect on
iBREC proliferation. Serum-starved cells were also incubated
with growth factors as described above in the presence of
clinically relevant concentrations of aflibercept or
ranibizumab. Disproving the assumption that additional bind-
ing of VEGF-B by aflibercept might result in superior inhibi-
tion of iBREC proliferation stimulated with VEGF-A165 in
combination with VEGF-B167/186, both VEGF-binding pro-
teins were similarly efficient (Fig. 1c).
Both VEGF-B variants did not affect iBRECmigration and
also did not modulate its stimulation by VEGF-A165 (Table 1).
In accordance with previous results showing that VEGF-A-
induced migration of iBREC was specifically blocked by 6 or
60 μg/ml ranibizumab (≈0.13 or 1.3 μM) or 15 μg/ml
aflibercept (≈0.13 μM), both inhibitors applied at these con-
centrations lowered migration back to basal levels despite
VEGF-B variants being present as co-factors (Table 1) [3,
31]. High concentrations of aflibercept (150 μg/ml≈1.3 μM)
Fig. 1 Proliferation of iBREC stimulated by VEGF-B167 or VEGF-B186
together with VEGF-A165 was completely blocked by ranibizumab.
Serum-starved cells were stimulated with VEGF-B167 (a) or VEGF-
B186 (b) for 48 h before conversion of WST-1 was determined as a
measure of proliferation. (c) iBREC were treated with VEGF-A165
together with VEGF-B variants (10 ng/ml each) with or without
100 μg/ml ranibizumab or 250 μg/ml aflibercept (~2 μM of each
inhibitor) for 48 h and proliferation of cells was assessed as described
above. Values (n=32) were normalized in relation to untreated cells.
Proliferation of iBREC exposed to ≥1 ng/ml VEGF-B was significantly
enhanced. Binding of VEGF-A was sufficient to completely inhibit
stimulation of proliferation when both VEGF-A and VEGF-B were
present
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resulted in unspecific overcompensation below the level of
basal migration as earlier reported [31].
VEGF-B167 and VEGF-B186 did not affect iBREC barrier
function
The barrier function of iBREC was assessed by measuring
TER of confluent cells. This approach is non-invasive and
has the distinct advantage that the same culture can be moni-
tored easily during long-term experiments by multiple subse-
quent measurements. In addition, presence of TJ-protein
claudin-1, a cell surface marker indicating a functional barrier,
was monitored [5, 7]. Because changes occasionally observed
early after addition of growth factors were considered less
relevant, we focused on barrier disturbance established in the
cultures during cultivation for more than 24 h. iBREC were
treated with 10 to 100 ng/ml VEGF-B for up to 3 days before
cell extracts were prepared for Western blot analyses. TER
was measured over the same period at different time points.
As shown in Fig. 2a, claudin-1 had disappeared after treatment
with VEGF-A165 , but amounts were not altered even after
extended treatment with VEGF-B167 or VEGF-B186
(Fig. 2a). We confirmed that localization of claudin-1 was
not affected under these conditions (data not shown), since
particularly the quantity of plasma membrane-localized
claudin-1 was shown to correlate strongly with TER [3, 5].
Accordingly, significantly changed TER values were not ob-
served (Fig. 2b).
VEGF-B167 and VEGF-B186 did not modulate the effect
of VEGF-A165 on iBREC barrier function
Although both VEGF-B splice variants did not affect the bar-
rier function of iBREC, their possible enhancing or
counteracting the action of the most important effector
VEGF-A165 remained to be ruled out. Therefore, iBREC were
incubated with VEGF-A165 together with either VEGF-B167 or
VEGF-B186 (50 ng/ml each) for 48 h before TER was mea-
sured or cell extracts were prepared. A similar loss of claudin-1
and reduction of TER was observed with all combinations
tested, indicating that both splice variants of VEGF-B did not
modulate the strong effect of VEGF-A165 on the iBREC bar-
rier (Fig. 2c). When the iBREC barrier had already been
disrupted with VEGF-A165, a normalizing effect was also not
observed during subsequent treatment with VEGF-B167 or
VEGF-B186 (50 ng/ml each) for additional 24 h (Fig. 2d).
To mimic hyperglycemia in diabetes patients, the influence
of elevated glucose levels on the actions of the different
growth factors was also studied: iBREC were cultivated for
3 days in medium containing 3 g/l (≈17 mM) D-glucose in-
stead of the normal 1 g/l (≈5.6 mM) D-glucose before VEGF-
A165 and VEGF-B were added. Claudin-1 was determined
1 day later by Western blot, and its presence was not affected
by the glucose concentration in the culture medium. Likewise,
loss of this TJ-protein as a consequence of treatment with
VEGF-A165 alone or together with VEGF-B was completely
independent of the amount of glucose in the medium (data not
shown).


















aflibercept60 μg/ml 6 μg/ml 150 μg/ml 15 μg/ml
– – – – – – – 1.00±0.30 – – –
x – – – – – – 1.44±0.56 p<0.008 – –
– x – – – – – 0.94±0.45 p>0.05 – –
– – x – – – – 0.78±0.43 p>0.05 – –
x x – – – – – 1.65±0.45 p<0.0001 – –
x x – x – – 1.23±0.44 p>0.05 p=0.001 –
x x – – x – – 1.21±0.34 p>0.05 p=0.0001 –
x x – – – x – 0.32±0.33 p<0.0001 – p<0.0001
x x – – – – x 1.24±0.52 p>0.05 – p=0.0007
x – x – – – – 1.34±0.16 p<0.0001 – –
x – x x – – – 1.05±0.16 p>0.05 p<0.0001 –
x – x – x – – 1.09±0.16 p>0.05 p<0.0001 –
x – x – – x – 0.28±0.20 p<0.0001 – p<0.0001
x – x – – – x 0.82±0.30 p>0.05 – p<0.0001
Migration of serum-starved iBREC during 24 h against VEGF-A165, VEGF-B167 or VEGF-B186 (25 ng/ml each) or combinations of these factors was
measured in a modified Boyden-Chamber assay with or without 100 μg/ml ranibizumab or 250 μg/ml aflibercept. Values (n=36) were normalized in
relation to those obtained with control cells not treated with effectors
aGF growth factor
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Inactivating VEGF-A165 was sufficient to reverse iBREC
barrier dysfunction induced by treatment with this factor
in combination with VEGF-B167 or VEGF-B186
Because both VEGF-B variants seemed not to contribute to
the disturbance of the iBREC barrier we assumed that binding
of VEGF-A165 by ranibizumab should be sufficient to reverse
the effect of VEGF-A165 even in the presence of VEGF-B167
or VEGF-B186. To test this hypothesis, confluent iBREC were
exposed to various combinations of VEGF-A165, VEGF-B167
and VEGF-B186 (50 ng/ml each) for 30 h and then treated with
different VEGF-binding proteins at clinically relevant concen-
trations for an additional 24 h before cellular extracts were
prepared. As a specificity control, the potential of the chimeric
antibody rituximab to revert VEGF-A induced changes was
also tested [35]. This antibody does not bind to any protein in
iBREC [31]. Ranibizumab and bevacizumab, both binding
only VEGF-A, and aflibercept targeting both VEGF-A and
VEGF-B all similarly re-established normal claudin-1 pres-
ence in iBREC, but rituximab did not have any effect
(Fig. 1a, b). As expected, the amount of plasma membrane
bound claudin-1 was dramatically reduced in iBREC treated
with VEGF-A165 and VEGF-B167 (50 ng/ml each), but it
reappeared when cells were exposed to ranibizumab at a clin-
ically relevant concentration of 100 μg/ml (Fig. 3c). Similar
results were obtained for iBREC treated with VEGF-A165
together with VEGF-B186 (data not shown).
To compare their relative efficacies, various amounts of the
VEGF-binding proteins ranibizumab and aflibercept were
added to iBREC pretreated for 30 h with VEGF-A165 in com-
bination with VEGF-B167 or VEGF-B186 (50 ng/ml each, ≈
1 μM). Cell extracts were prepared 24 h later, and expression
of claudin-1 was analyzed by Western blot (Fig. 4a, b). Lost
claudin-1 was completely brought back by 1 μg/ml
ranibizumab or 2.5 μg/ml aflibercept (≈2 μM), concentrations
even 100× lower than values typically achieved after intraoc-
ular injection. Also sufficient were 0.1 μg/ml ranibizumab
or 0.25 μg/ml aflibercept (≈200 nM), although VEGF-
A165 cannot be bound completely by the inhibitors un-
der these conditions: About 5 ng/ml free VEGF-A165
remained in the culture supernatant as determined by
ELISA. This amount is obviously too low to affect
strongly the expression of claudin-1 by iBREC. When
VEGF-A165 was present at 10-fold excess over the
VEGF-binding proteins, loss of claudin-1 could not be
reverted indicating an insufficient inhibition.
Fig. 2 VEGF-B167 or VEGF-B186 did neither affect TER or claudin-1
expression nor modulate VEGF-A-induced barrier disturbances. (a, b)
iBREC were exposed for up to 3 days to 10 to 100 ng/ml VEGF-B167
before cell extracts were prepared to determine claudin-1 byWestern blot
(a) or TER was measured at indicated time points (b). Claudin-1
expression was only lower in the presence of VEGF-A165 , whereas
VEGF-B167 variants did not affect expression of this TJ protein or
directly measured TER. Similar results were obtained with VEGF-B186.
(c, d) iBREC were incubated with VEGF-A165 together with either
VEGF-B167 or VEGF-B186 (c) or the cells were pretreated with VEGF-
A165 for 2 days before VEGF-B167 or VEGF-B186 (50 ng/ml each) were
added (d). TER was measured 24 h later. The VEGF-A165-caused TER
decrease was neither prevented nor reverted by any VEGF-B splice
variant
890 Graefes Arch Clin Exp Ophthalmol (2015) 253:885–894
Fig. 3 Binding of VEGF-A165 was sufficient to reinstate lost claudin-1 in
the presence of VEGF-B (a, b) iBREC were treated with combinations of
growth factors (each at 50 ng/ml) for 30 h before 100 μg/ml ranibizumab
or 250 μg/ml aflibercept, bevacizumab or rituximab were added. Cell
extracts were prepared 24 h later and analyzed by Western blot. Treat-
ment with any of the VEGF-A-binding proteins, but not with the con-
trol antibody rituximab, resulted in reappearance of lost claudin-1. (c)
iBREC were treated with VEGF-A165 together with VEGF-B167 for
30 h before 100 μg/ml ranibizumab was added for 24 h. The TJ protein
claudin-1 was then visualized by immunofluorescence staining.
Claudin-1 vanished from the plasma membrane during growth factor
treatment, but normal staining was seen after subsequent incubation
with the VEGF-A-binding protein
Fig. 4 Aflibercept and
ranibizumab reinstated lost
claudin-1 with similar efficacy
(a,b) iBREC were treated with
VEGF-A165+VEGF-B167 (a) or
VEGF-A165+VEGF-B186 (b) for
30 h before ranibizumab or
aflibercept were added for another
24 h. To neutralize 50 ng/ml
(≈1 μM) of the VEGF variants,
inhibitors were used at various
concentrations in the range of
≈0.01 to 1 μM corresponding to
10 to 1,000 ng/ml ranibizumab or
25 to 2,500 ng/ml aflibercept. (c,
d) Ranibizumab or aflibercept
were added to iBREC pretreated
for 30 hwith VEGF-A165 together
with VEGB167 (c) or VEGF-B186
(d) as described above and TER
was measured 24 h later.
Normalizing effects of the VEGF-
binding proteins on induced
disturbances of the iBREC barrier
were similar
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We also measured directly whether ranibizumab and
aflibercept can normalize the iBREC barrier disturbed by
VEGF-A in the presence of the potentially co-acting VEGF-
B: when ranibizumab or aflibercept were added to iBREC
which had been treated for 30 h with VEGF-A165 in combi-
nation with VEGF-B167 or VEGF-B186 (50 ng/ml each), the
substantially reduced TER normalized in all cases within 24 h.
To achieve normalization of TER, even much lower concen-
trations of the inhibitors than those reached after intra vitreal
injection were found to be sufficient (Fig. 4c, d).
Discussion
Targeting members of the VEGF family is a promising option
in the therapy of diabetic macular edema [27–29]. Whereas
the different functions of VEGF-A have been intensively stud-
ied, the role of VEGF-B still appears rather diffuse [12–21]. In
the normal eye, VEGF-B167 is the predominantly expressed
variant whereas substantial amounts of VEGF-B186 seem to
be present only in malignant tumors [12]. Because retinal
endothelial cells form an important part of the blood-retina-
barrier, a functional impact of VEGF-B on this cell type might
be highly relevant to therapeutic concepts. Therefore, we in-
vestigated whether the two main variants VEGF-B167 and
VEGF-B186 affected the barrier properties of iBREC or mod-
ulated the changes induced by the key factor VEGF-A165.
Since migration and proliferation of REC are involved in ret-
inal neovascularization as a characteristic of proliferative DR,
potential stimulation of these processes by VEGF-B variants
was also investigated.
VEGF-B167 and VEGF-B186 indeed enhanced proliferation
of iBREC after exposure for 2 days which is in accordance
with other observations [19]. In contrast, proliferation of pri-
mary HREC was not stimulated by VEGF-B167 after treat-
ment for only 24 h [18]. In addition to the shorter time of
exposure, weaker stimulation of cell proliferation might have
been due to conditions associated with cultivating primary
REC, e.g. presence of inhibiting antibiotics and other cell
types like pericytes. It can be concluded from their effect on
proliferation that the used recombinant human and murine
VEGF-B variants activate signal transduction in bovine
REC. Like PlGF, another member of the VEGF family, the
studied VEGF-B variants did not stimulate migration of
iBREC which may be a consequence of their binding to
VEGFR1 without co-activating VEGFR2 [6, 37].
Interestingly, ranibizumab completely blocked both iBREC
migration and proliferation when these processes had been
stimulated by VEGF-A together with VEGF-B. Additional
inhibition of VEGF-B, as achieved with aflibercept, was ob-
viously not necessary to normalize proliferation, indicating
that in the presence of the dominant VEGF-A, parallel activa-
tion of independent signalling pathways is not relevant to the
overall effect. It could be speculated that VEGF-A expression
is somehow induced by VEGF-B, but neither did VEGF-A
binding ranibizumab block proliferation stimulated only by
VEGF-B nor could VEGF-A be detected in these experiments
(data not shown). A possible, but unconfirmed mechanism
underlying the complete inhibition of proliferation by
ranibizumab is its binding and inactivation of putative
VEGF-A/VEGF-B heterodimers which have been described
[9]. If, instead of VEGF-B, PlGF acts as a co-stimulator, bind-
ing of both PlGF and VEGF-A is necessary to block prolifer-
ation completely, emphasizing the distinct properties of the
related factors [6]. The three VEGF family members VEGF-
A, VEGF-B, and PlGF all bind to the Ig domain 2 of
VEGFR1, but whereas VEGF-A and PlGF interact with the
same region of VEGFR1, differing contact points between the
receptor and VEGF-B have been identified [38]. This may be
the reason for different subsequent signal transduction and the
substantially lower affinity of VEGF-B compared to VEGF-
A, which in turn provides a simple explanation of our obser-
vation that iBREC proliferation induced by VEGF-Awas not
notably affected by equimolar amounts of VEGF-B. That
VEGF-B, like PlGF, failed to initiate basal or alter VEGF-A-
stimulated migration supports our previously made assump-
tion that iBREC migration is almost exclusively mediated
through VEGFR2 together with NRP [6].
The barrier function of REC was also not affected by the
VEGF-B variants, which was clearly indicated by a constant
TER and stable claudin-1 expression over several days of
incubation. This is in accordance with the previous observa-
tion that vascular permeability was not affected by VEGF-
B167 [14]. This was also confirmed by overexpressing
VEGF-B167 in the murine choroid by means of an adenoviral
vector. In contrast VEGF-B186 induced permeability in this
experimental context [20]. Retinal and choroidal endothelial
cells might respond differently to VEGF-B, but it seems more
likely that this is an effect only of very high amounts of the
growth factor which do not reflect physiological conditions
[39]. Interestingly, the factors VEGF-B167/186 and PlGF-1/-2,
which do not influence permeability of iBREC monolayers,
all bind and activate VEGFR1, but not VEGFR2, supporting
our previously made assumption that disturbance of the REC
barrier is mainly mediated through VEGFR2 with VEGF-A
being its most important ligand [7]. Both variants of VEGF-B
also did not modulate the strong effect of VEGF-A165 on the
TJ-protein claudin-1 and TER. Loss of claudin-1 or reduction
of TER induced by VEGF-A165 was neither prevented nor
more pronounced evenwhen VEGF-B167 or VEGF-B186 were
added subsequently, or when cells were kept under glucose
stress. Therefore, the assumption that binding of VEGF-A is
sufficient to normalize a barrier function disrupted by VEGF-
A165 in combination with VEGF-B167 or VEGF-B186 seemed
reasonable and could be confirmed. Even at concentrations
well below values achieved after intraocular injection,
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ranibizumab completely reversed reduction of TER and rein-
stated lost claudin-1 in iBREC exposed to combinations of
these growth factors. The efficacy of aflibercept was similar,
but not better, indicating that its additional binding of VEGF-
B is not relevant to the normalization of the REC barrier.
Our results support the assumption that neither VEGF-B167
nor VEGF-B186 can play a significant role in the control of
permeability of the REC barrier even when long-term expo-
sure as a consequence of pathogenic processes in the eye has
to be considered. In addition, marked effects of VEGF-B167 or
VEGF-B186 on REC proliferation and migration, the hall-
marks of angiogenic processes, were also not recognized.
Accordingly, normalization of a REC barrier disrupted by
VEGF-A in the presence of VEGF-B was achieved by
targeting the key factor VEGF-Awithout additional inactiva-
tion of VEGF-B being an advantage or disadvantage and the
same conclusion can be drawn for blocking proliferation or
migration in an environment containing both VEGF-A and
VEGF-B. Besides the primary therapeutic effects of VEGF
inhibitors with a broader binding specificity, their interference
with neuroprotection potentially provided by VEGF-B may
also play a role in some cases and should be taken into account
[21].
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